6y
At Wave, we are excited about the continued advancement of our Huntington’s disease programs in the clinic, as well as the initiation of two additional CNS clinical programs in the second half of 2020. Further we believe that the continued evolution of our PRISM discovery and drug development platform will yield new opportunities to make a difference in the lives of countless rare disease patients and their families.